Masitinib for mild Alzheimer’s disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 3 trial tests masitinib to slow the progression of mild Alzheimer’s disease. It may help people with early, mild symptoms by targeting the disease process, not just symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Alzheimer’s disease after a standard specialist checklist at screening
- Your daily functioning score is below 73 at screening and at the start of the study visit
- Your thinking test score (MMSE) is between 21 and 25 at both screening and baseline
- You have “Alzheimer’s type” brain changes on a test: a positive amyloid PET scan, or matching blood/CSF marker results showing amyloid and tau changes
- If you take Alzheimer’s medicines like donepezil, rivastigmine, galantamine, or memantine, your dose must be stable for at least 6 months
- You must have a caregiver who can reliably attend visits, help with the study tasks, and communicate in the study’s language
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.